Ant Group Offloads Stakes to Focus on AI Chips Amid Nvidia Shortage

Ant Group divests from Orbbec and Youon, channeling funds to Alibaba and Huawei for Artificial Intelligence chip alternatives.

Ant Group has offloaded its shares in companies Orbbec and Youon, releasing capital for reinvestment into emerging technologies, especially amidst ongoing hardware shortages. The Chinese conglomerate, which has significant backing from Alibaba, is redirecting the funds from these sales towards innovative technology ventures and early-stage opportunities, as part of its broader strategy to enhance its technological capabilities.

The divestment includes over 556 million yuan for 8.82 million shares from Orbbec and 219 million yuan from Youon Technology. These transactions were strategically favorable, yielding significant returns on Ant Group´s initial investments. Each company has prospered since the initial rounds of funding, making these equity sales a profitable venture for Ant Group.

Part of Ant Group´s strategy involves capitalizing on Artificial Intelligence hardware alternatives by sourcing AI chips from Alibaba and Huawei, amid global shortages caused by restrictions on Nvidia exports from the U.S. The group´s pivot towards securing local chip alternatives signals a strategic move to sustain its AI and tech endeavors, reflecting Ant Group´s adaptability in an evolving tech landscape.

62

Impact Score

Crescent library brings privacy to digital identity systems

Crescent is a cryptographic library that adds unlinkability to common digital identity formats, preventing tracking across credential uses while preserving selective disclosure. It supports JSON Web Tokens and mobile driver’s licenses without requiring issuers to change their systems.

Artificial Intelligence-powered remote drug testing removes barriers to recovery

Q2i and King’s College London are collaborating to evaluate an Artificial Intelligence-powered at-home drug testing system aimed at people recovering from opioid use disorder. The solution delivers digitally observed, clinically reliable results and pairs testing with contingency management and telehealth to reduce logistical barriers to care.

Contact Us

Got questions? Use the form to contact us.

Contact Form

Clicking next sends a verification code to your email. After verifying, you can enter your message.